Please login to the form below

Not currently logged in
Email:
Password:

Novartis appoints Shaun Coughlin to lead its US biomedical research institute

The renowned academic joins as the pharma firm's global head of cardiovascular and metabolism

Shaun CoughlinNovartis has appointed Shaun Coughlin to head up its biomedical research institute based in Cambridge, Massachusetts, as its new global head of cardiovascular and metabolism.

He joins the pharma giant from the University of California San Francisco’s (UCSF) cardiovascular research centre, where he was previously a director. He has served UCSF for 33 years.

Talmadge King Jr, dean, school of medicine at USFC, said: “We are sad to lose on our most respected leaders, yet profoundly grateful for his decades of service and immeasurable contributions to our mission.

“Dr Coughlin is an outstanding example of the personal qualities that collectively have propelled UCSGF to the top.”

Coughlin is also a member of the National Academy of Scienes, the National Academy of Medicine and the American Academy of Arts & Scienes and has won numerous awards including Brisol-Myers Squibb’s Cardiovascular Research Award.

23rd August 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....